{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:52:17Z","timestamp":1774569137064,"version":"3.50.1"},"reference-count":25,"publisher":"Galenos Yayinevi","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2023.2023.0029","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T11:09:58Z","timestamp":1699960198000},"page":"242-250","source":"Crossref","is-referenced-by-count":4,"title":["Experience of Daratumumab in Relapsed\/Refractory Multiple Myeloma: A Multicenter Study from T\u00fcrkiye"],"prefix":"10.4274","volume":"40","author":[{"given":"Atakan","family":"Tekinalp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayfer","family":"Ged\u00fck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aydan","family":"Akdeniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esra","family":"Terzi Demirsoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vildan","family":"G\u00fcrsoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00fczeyyen","family":"Aslaner Ak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Metin","family":"Ba\u011fc\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sema","family":"Se\u00e7ilmi\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Keklik Karada\u011f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015fe","family":"Oru\u00e7 Uysal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Do\u011fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinan","family":"Demircio\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ha\u015fim Atakan","family":"Erol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ceyda","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahir","family":"\u00d6zkalemka\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eehmus","family":"Ertop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Da\u011fl\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Sinan","family":"Dal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcray","family":"Saydam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Merter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cihan","family":"Ural","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6zcan","family":"\u00c7eneli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","unstructured":"1. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 2020;95:548-567.","journal-title":"Am J Hematol"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328-346.","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","unstructured":"3. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123:837-842.","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.3389\/fimmu.2018.02722","article-title":"CD38: A target for immunotherapeutic approaches in multiple myeloma","volume":"9","author":"Morandi","year":"2018","unstructured":"4. Morandi F, Horenstein AL, Costa F, Giuliani N, Pistoia V, Malavasi F. CD38: A target for immunotherapeutic approaches in multiple myeloma. Front Immunol 2018;9:2722.","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc\u03b3 receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","unstructured":"5. Overdijk MB, Jansen JH, Nederend M, Lammerts van Bueren JJ, Groen RW, Parren PW, Leusen JH, Boross P. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc\u03b3 receptor-mediated cross-linking. J Immunol 2016;197:807-813.","journal-title":"J Immunol"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, Voorhees PM, Laubach JP, van de Donk NWCJ, Ahmadi T, Uhlar CM, Wang J, Feng H, Qi M, Richardson PG, Lonial S. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol 2020;7:e447-e455.","DOI":"10.1016\/S2352-3026(20)30081-8"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","unstructured":"7. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:754-766.","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"MA","year":"2016","unstructured":"8. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:1319-1331.","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00277-020-04374-y","article-title":"Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group","volume":"100","author":"Vozella","year":"2021","unstructured":"9. Vozella F, Siniscalchi A, Rizzo M, Za T, Antolino G, Coppetelli U, Piciocchi A, Andriani A, Annibali O, De Rosa L, Cimino G, La Verde G, De Stefano V, Cantonetti M, di Toritto TC, Petrucci MT. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group. Ann Hematol 2021;100:1059-1063.","journal-title":"Ann Hematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s12185-019-02715-w","article-title":"Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed\/refractory multiple myeloma patients","volume":"110","author":"Lovas","year":"2019","unstructured":"10. Lovas S, Varga G, Farkas P, Masszi T, Wohner N, Bereczki \u00c1, Adamkovich N, Borb\u00e9nyi Z, Szomor \u00c1, Alizadeh H, Szaleczky E, Wolf K, Schneider T, Plander M, Szendrei T, Csacsovszki O, Csukly Z, Rajnics P, Egyed M, Nagy Z, Rejt\u0151 L, Ill\u00e9s \u00c1, Mikala G, V\u00e1r\u00f3czy L. Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed\/refractory multiple myeloma patients. Int J Hematol 2019;110:559-565.","journal-title":"Int J Hematol"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Beksac M, Aydin Y, Goker H, Turgut M, Besisik SK, Cagirgan S, Tuglular T, Vural F, Yagci M, Alacacioglu I, Aytan P, Goksoy HS, Gulbas Z, Gunes AK, Gurkan E, Hacioglu SK, Karti SS, Kaynar L, Ozdogu H, Paydas S, Solmaz S, Sonmez M, Tekgunduz E, Yildirim R, Ilhan O. Early access program results from Turkey and a literature review on daratumumab monotherapy among heavily pretreated patients with relapsed\/refractory myeloma. Clin Lymphoma Myeloma Leuk 2020;20:e474-e484.","DOI":"10.1016\/j.clml.2020.02.017"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/bjh.18172","article-title":"Outcomes of daratumumab in the treatment of multiple myeloma: a retrospective cohort study from the Canadian Myeloma Research Group Database","volume":"198","author":"LeBlanc","year":"2022","unstructured":"12. LeBlanc R, Mian H, Reece D, Masih-Khan E, Kardjadj M, Jimenez-Zepeda VH, McCurdy A, Song K, Sebag M, Louzada M, White D, Stakiw J, Kotb R, Reiman A, Aslam M, Gul E, Venner CP. Outcomes of daratumumab in the treatment of multiple myeloma: a retrospective cohort study from the Canadian Myeloma Research Group Database. Br J Haematol 2022;198:93-102.","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"626","DOI":"10.4149\/neo_2021_201113N1223","article-title":"Real-world effectiveness and safety of daratumumab, bortezomib, and dexamethasone in relapsed\/refractory multiple myeloma in Slovakia","volume":"68","author":"Harvanov\u00e1 \u013d","year":"2021","unstructured":"13. Harvanov\u00e1 \u013d, \u0160tulajterov\u00e1 V, Guman T, Ladick\u00e1 M, Hleba\u0161kov\u00e1 M, Chudej J, \u0160imek M, \u0160tecov\u00e1 N, Flochov\u00e1 E, Kubala J, Siman\u010d\u00edkov\u00e1 I, Drgo\u0148a \u013d, Vranovsk\u00fd A, Wild A, Mistr\u00edk M, B\u00e1torov\u00e1 A. Real-world effectiveness and safety of daratumumab, bortezomib, and dexamethasone in relapsed\/refractory multiple myeloma in Slovakia. Neoplasma 2021;68:626-630.","journal-title":"Neoplasma"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Szabo AG, Klausen TW, Levring MB, Preiss B, Helleberg C, Breinholt MF, Hermansen E, Gjerdrum LMR, B\u00f8nl\u00f8kke ST, Nielsen K, Kjeldsen E, Iversen KF, Teodorescu EM, Dokhi M, Kurt E, Strandholdt C, Andersen MK, Vangsted AJ. The real-world outcomes of multiple myeloma patients treated with daratumumab. PLoS One 2021;16:e0258487.","DOI":"10.1371\/journal.pone.0258487"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"100330","DOI":"10.1016\/j.lrr.2022.100330","article-title":"Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: a \"real world\" experience","volume":"17","author":"Fucci","year":"2022","unstructured":"15. Fucci L, Gensini L, Coppetelli U, La Barbera EO, Gentile M, Fiori L, Perrone S, Cimino G. Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: a \"real world\" experience. Leuk Res Rep 2022;17:100330","journal-title":"Leuk Res Rep"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bjh.16292","article-title":"Daratumumab in high-risk relapsed\/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain\/amplification and GEP70 status on outcome","volume":"189","author":"Mohan","year":"2020","unstructured":"16. Mohan M, Weinhold N, Schinke C, Thanedrarajan S, Rasche L, Sawyer JR, Tian E, van Rhee F, Zangari M. Daratumumab in high-risk relapsed\/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain\/amplification and GEP70 status on outcome. Br J Haematol 2020;189:67-71.","journal-title":"Br J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/jha2.47","article-title":"Use of daratumumab in high risk multiple myeloma: a meta\u2010analysis","volume":"1","author":"Premkumar","year":"2020","unstructured":"17. Premkumar V, Pan S, Lentzsch S, Bhutani D. Use of daratumumab in high risk multiple myeloma: a meta\u2010analysis. eJHaem 2020;1:267-271.","journal-title":"eJHaem"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2020","unstructured":"18. Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia 2020;34:1-20.","journal-title":"Leukemia"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41375-021-01343-w","article-title":"Limited efficacy of daratumumab in multiple myeloma with extramedullary disease","volume":"36","author":"Jelinek","year":"2022","unstructured":"19. Jelinek T, Sevcikova T, Zihala D, Popkova T, Kapustova V, Broskevicova L, Capkova L, Rihova L, Bezdekova R, Sevcikova S, Zidlik V, Havel M, Plonkova H, Jungova A, Minarik J, Stork M, Pour L, Pavlicek P, Spicka I, Maisnar V, Radocha J, Simicek M, Hajek R. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia 2022;36:288-291.","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13045-022-01374-5","article-title":"Phase II trial of daratumumab with DCEP in relapsed\/refractory multiple myeloma patients with extramedullary disease","volume":"15","author":"Byun","year":"2022","unstructured":"20. Byun JM, Min CK, Kim K, Bang SM, Lee JJ, Kim JS, Yoon SS, Koh Y. Phase II trial of daratumumab with DCEP in relapsed\/refractory multiple myeloma patients with extramedullary disease. J Hematol Oncol 2022;15:150.","journal-title":"J Hematol Oncol"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Beksac M, Tuglular T, Gay F, Mina R, Katodritou E, Unal A, Cavo M, Ozsan GH, van der Velden VHJ, Beverloo B, Vermeulen M, van Duin M, Cengiz G, Sevindik OG, Merante S, Manousou K, Sonneveld P, Terpos E. Efficacy of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone for the treatment of multiple myeloma patients presenting with extramedullary disease: a European Myeloma Network Study (EMN19). Blood 2022;140(Suppl 1):10177-10178.","DOI":"10.1182\/blood-2022-160004"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1080\/00313020701570038","article-title":"Significance of bone marrow fibrosis in multiple myeloma","volume":"39","author":"Subramanian","year":"2007","unstructured":"22. Subramanian R, Basu D, Dutta TK. Significance of bone marrow fibrosis in multiple myeloma. Pathology 2007;39:512-515.","journal-title":"Pathology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.1182\/blood.V118.21.5077.5077","article-title":"Incidence of bone marrow (BM) fibrosis in multiple myeloma (MM) patients and its relationship to cytogenetic (CG) abnormalities in a minority population","volume":"118","author":"Sidhu","year":"2011","unstructured":"23. Sidhu G, Latif R, Liu J, Axiotis C, Khillan R, Braverman AS. Incidence of bone marrow (BM) fibrosis in multiple myeloma (MM) patients and its relationship to cytogenetic (CG) abnormalities in a minority population. Blood 2011;118:5077.","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s12185-022-03373-1","article-title":"Presence of bone marrow fibrosis in multiple myeloma may predict extramedullary disease","volume":"116","author":"Koshiishi","year":"2022","unstructured":"24. Koshiishi M, Kawashima I, Hyuga H, Nakadate A, Matsuura M, Hosokawa E, Sakamoto Y, Suzuki J, Suzuki M, Kumagai T, Yamamoto T, Nakajima K, Tanaka M, Kirito K. Presence of bone marrow fibrosis in multiple myeloma may predict extramedullary disease. Int J Hematol 2022;116:544-552.","journal-title":"Int J Hematol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1177\/1078155220967738","article-title":"A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting","volume":"27","author":"Geirnaert","year":"2021","unstructured":"25. Geirnaert M, Howarth J, Martin K, Ricard C, Streilein S, Wasney D, Dao V, Kotb R, Rimmer E, Minuk L. A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting. J Oncol Pharm Pract 2021;27:907-910.","journal-title":"J Oncol Pharm Pract"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T14:47:48Z","timestamp":1703774868000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-20586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12,28]]}},"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2023.2023.0029","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"value":"1300-7777","type":"print"},{"value":"1308-5263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,28]]}}}